Latest Reported Offering
$50,000
Target Amount
$1,235,000
Maximum Amount
2026-04-30
Deadline
Security Details
Type: Common Stock
Price per share: $10.54
Price set by: Dividing pre-money valuation $250,000,000.00 (or $8.43 per share, derived by dividing pre-money valuation of $200,000,000 for investors in the first $300,000.00) by number of shares outstanding on fully diluted basis.
Shares offered: 5,932+
Offering Costs
Cash commission: 7.9%
of the offering amount upon a successful fundraise, and be entitled to reimbursement for out-of-pocket third party expenses it pays or incurs on behalf of the Issuer in connection with the offering.
Equity compensation: —
No
Filing history
Form C family — 1 filing| Filed | Form | File number | Portal | What it states | What the filer said |
|---|---|---|---|---|---|
| 2025-10-08 | C | 020-36456 | Wefunder | $50K target, up to $1.2M · Common Stock at $10.54 · closes 2026-04-30 | — |
The reported figures behind EMulate Therapeutics, Inc.
Form C prints a most-recent and a prior fiscal year side by side but never names them. The dashboard chains every filing into those years and plots them. EDGAR still has each Form C-AR; the dashboard lays every year they filed next to it.
- Reported financials chained into fiscal years — revenue, income, assets, cash — not one filing at a time
- A sparkline on each figure so the shape is visible before the numbers
- A revenue series dated to the filings that reported it
- The campaign as filed: target, ceiling, deadline, and the portal that ran it
- Follow it, and see it change on your watchlist
Company Information
Latest Metrics
Employees3
Total Assets$1,193,000
Cash on Hand$54,000
Revenues$0.00
Net Income-$19,139,000
Crowdfunding Portals
The intermediary named in this company’s Form C filings. Investments in a Regulation Crowdfunding offering can only be made through them.